Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis

Systemic sclerosis (SSc) is characterized by dysregulation of type I interferon (IFN) signaling. CD52 is known for its immunosuppressive functions in T cells. This study was undertaken to investigate the role of CD52 in monocyte adhesion and type I IFN signaling in patients with SSc.

[1]  S. Assassi,et al.  Type I interferon dysregulation in Systemic Sclerosis. , 2020, Cytokine.

[2]  V. Beneš,et al.  Global miRNA and mRNA expression profiles identify miRNA‐26a‐2‐3p‐dependent repression of IFN signature in systemic sclerosis human monocytes , 2020, European journal of immunology.

[3]  O. Distler,et al.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis , 2019, Nature Reviews Rheumatology.

[4]  Somy Yoon,et al.  HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases , 2019, International journal of molecular sciences.

[5]  J. Varga,et al.  Emerging targets of disease-modifying therapy for systemic sclerosis , 2019, Nature Reviews Rheumatology.

[6]  Y. Sanders,et al.  HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis , 2019, Therapeutic advances in chronic disease.

[7]  D. Rubin,et al.  Emerging Therapies for Inflammatory Bowel Disease , 2018, Advances in Therapy.

[8]  S. O’Reilly,et al.  A therapy for systemic sclerosis: STAT! , 2018, Rheumatology.

[9]  G. Ferraccioli,et al.  Characterization of inflammatory cell infiltrate of scleroderma skin: B cells and skin score progression , 2018, Arthritis Research & Therapy.

[10]  G. Giovannoni,et al.  Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis , 2017, Immunology.

[11]  Oliver Distler,et al.  Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis , 2017, Journal of scleroderma and related disorders.

[12]  K. Ley,et al.  Biology and structure of leukocyte β 2 integrins and their role in inflammation , 2016, F1000Research.

[13]  Elizabeth E. Hull,et al.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.

[14]  N. Henderson,et al.  αv integrins: key regulators of tissue fibrosis , 2016, Cell and Tissue Research.

[15]  J. V. van Buul,et al.  Crossing the Vascular Wall: Common and Unique Mechanisms Exploited by Different Leukocyte Subsets during Extravasation , 2015, Mediators of inflammation.

[16]  Shinichi Sato,et al.  Vasculopathy in scleroderma , 2015, Seminars in Immunopathology.

[17]  F. Ginhoux,et al.  Monocytes and macrophages: developmental pathways and tissue homeostasis , 2014, Nature Reviews Immunology.

[18]  M. Bianchi,et al.  Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. , 2014, Antioxidants & redox signaling.

[19]  Minghua Wu,et al.  The Role of Type 1 Interferon in Systemic Sclerosis , 2013, Front. Immunol..

[20]  L. Harrison,et al.  T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10 , 2013, Nature Immunology.

[21]  L. Rönnblom,et al.  The interferon signature in autoimmune diseases , 2013, Current opinion in rheumatology.

[22]  M. Sweet,et al.  Histone deacetylases as regulators of inflammation and immunity. , 2011, Trends in immunology.

[23]  E. Fox.  Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis , 2010, Expert review of neurotherapeutics.

[24]  H. Mitsuya,et al.  Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis , 2010, Arthritis research & therapy.

[25]  Steffen Jung,et al.  Monocytes: subsets, origins, fates and functions , 2010, Current opinion in hematology.

[26]  S. Jalkanen,et al.  Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrate. , 2009, Blood.

[27]  Yanping Hu,et al.  Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model , 2009, Immunology.

[28]  R. Gay,et al.  Histone deacetylase 7, a potential target for the antifibrotic treatment of systemic sclerosis. , 2009, Arthritis and rheumatism.

[29]  M. Gershwin,et al.  The immunobiology of systemic sclerosis. , 2008, Seminars in arthritis and rheumatism.

[30]  Wei Chen,et al.  A nonsynonymous functional variant in integrin-αM (encoded by ITGAM) is associated with systemic lupus erythematosus , 2008, Nature Genetics.

[31]  R. Gay,et al.  Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. , 2007, Arthritis and rheumatism.

[32]  I. Adcock.  HDAC inhibitors as anti‐inflammatory agents , 2007, British journal of pharmacology.

[33]  Xiaodong Zhou,et al.  Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. , 2006, Rheumatology.

[34]  L. Platanias.  Mechanisms of type-I- and type-II-interferon-mediated signalling , 2005, Nature Reviews Immunology.

[35]  M. Aurrand-Lions,et al.  Adhesion mechanisms regulating the migration of monocytes , 2004, Nature Reviews Immunology.

[36]  W. Muller,et al.  Locomotion of monocytes on endothelium is a critical step during extravasation , 2004, Nature Immunology.

[37]  David Botstein,et al.  Systemic and cell type-specific gene expression patterns in scleroderma skin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[39]  C. Kirchhoff,et al.  New Insights into the Origin, Structure and Role of CD52: A Major Component of the Mammalian Sperm Glycocalyx , 2000, Cells Tissues Organs.

[40]  M. Nimtz,et al.  Male-specific Modification of Human CD52* , 1999, The Journal of Biological Chemistry.

[41]  E. Nilsson,et al.  Integrins and other adhesion molecules on lymphocytes from synovial fluid and peripheral blood of rheumatoid arthritis patients , 1992, European journal of immunology.

[42]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[43]  M. Mayes,et al.  An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative , 2013 .

[44]  A. Rosen,et al.  Type I interferons: crucial participants in disease amplification in autoimmunity , 2010, Nature Reviews Rheumatology.

[45]  S. Jimenez,et al.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology (Basel).